Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas. Show more
Location: Building 14, Stafford, TX, 77477, United States | Website: https://greenwichlifesciences.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
144.5M
52 Wk Range
$8.06 - $17.00
Previous Close
$10.84
Open
$10.75
Volume
88,757
Day Range
$10.13 - $10.92
Enterprise Value
118.5M
Cash
2.75M
Avg Qtr Burn
-1.83M
Insider Ownership
52.30%
Institutional Own.
9.47%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
GLSI-100 Details Breast cancer | Phase 3 Update |